The hunt for CJC-1295 in Enna consistently ends with the same conclusion: research peptides are distributed through specialist online vendors, not local retail. The benefit of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers better verification tools than any local market ever offers. Separating properly characterised CJC-1295 from the rest of the market comes down to three things: an HPLC chromatogram documenting ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. This guide gives Enna researchers the practical tools to evaluate CJC-1295 vendors systematically and source research-grade CJC-1295 with confidence.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Enna comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
Before evaluating any specific vendor, establish a quality benchmark — so you can identify whether a supplier meets the standard. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone provides no identity confirmation. Red flags in CJC-1295 vendor evaluation: prices far under typical market pricing, vague sourcing information, no community presence, and COAs that lack endotoxin data. The lyophilised (freeze-dried) form of CJC-1295 is much more stable than liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Enna
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg in 2mL gives a 2.5mg/mL solution — providing 25mcg per unit measured on a 100-unit syringe. The most significant preventable safety hazard in CJC-1295 research is endotoxin contamination from poor sourcing — a verified endotoxin panel in the batch COA is the key safeguard. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is not approved for human use and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
